Heart failure is a common progressive and serious medical condition affecting the mankind that can eventually cause or contribute to death if left untreated . In conclusion, our findings indicate that the administration of Carvedilol to patients with moderate to severe heart failure can ameliorate the symptoms, diminish the disability, and reduce the morbidity associated with this disorder. Long-term treatment with Carvedilol in patients with heart failure as a result of ischemicor idiopathic dilated cardiomyopathy results ina significant improvement in left ventricular function in terms of left ventricular ejection fraction and lessening of symptoms of heart failure. These benefits were apparent across a wide range of measures, both in patients with and those without coronary artery disease and in those who remained symptomatic despite therapy with digitalis, diuretics, and an ACE inhibitor. However, the favorable effects of carvedilol in the present study were observed primarily when measures of efficacy were used that closely resemble those used in clinical practice, whereas methods of assessment developed for use in clinical trials were less able to distinguish a treatment effect. This f i n d i n g has important implications for the design of future clinical trials.
